← Back to all signals
RESEARCH PAPER ANALYSIS

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.

AI interpretation is pending for this paper.

Open original publication →
PMID39157875
JournalHaematologica
Publication Date2025-01-01
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

The introduction of pediatric-inspired regimens in adult Philadelphia-negative acute lymphoblastic leukemia (Ph- ALL) has significantly improved patients' prognosis. Within the Campus ALL network, we analyzed the outcome of adult Ph- ALL patients treated according to the GIMEMA LAL1913 protocol outside the clinical trial to compare the real-life data with the study results. We included 421 consecutive patients; median age 42 years. The complete remission (CR) rate after the first course of chemotherapy was 94%, and measurable residual disease (MRD) negativity after the third course was achieved in 72% of patients. The 3-year overall survival (OS) and disease-free survival (DFS) were 67% and 57%, respectively. In a multivariate analysis, MRD positivity negatively influenced DFS. In a time-dependent analysis including only very high-risk (VHR) and MRD positive cases, transplanted (hematopoietic stem cell transplantation [HSCT]) patients had a significantly better DFS than non-HSCT patients (P=0.0017). During induction, grade ≥2 pegaspargase-related hepato-toxicity was observed in 25% of patients (vs. 12% in the GIMEMA LAL1913 trial, P=0.0003). In this large, real-life cohort of Ph- ALL, we confirmed the very high CR rate and a superimposable OS and DFS compared to the GIMEMA LAL1913 clinical trial (CR rate after C1, 94% vs. 85%, P=0.0004; 3-year OS, 67% vs. 67%, P=0.94; 3-year DFS, 57% vs. 63%, P=0.17). HSCT confirms its important role in VHR and MRD-positive patients. The rate of pegaspargase-related toxicity was significantly higher in the real-life setting, emphasizing the importance of dose adjustment in the presence of risk factors to avoid excessive toxicity.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Pharmacological thromboprophylaxis following ventriculoperitoneal shunt insertion: a single-centre experience of thromboembolic and bleeding outcomes. Acta neurochirurgica 66.5 2 Design principles of prosthetic reconstruction after pelvic tumor resection: a systematic review and perspective from modular systems to 3D-printed personalized solutions. Journal of orthopaedic surgery and research 73.9 3 Ultrasound-guided versus conventional sinus tract laser closure for adolescent sacrococcygeal pilonidal disease: a retrospective comparative study. Techniques in coloproctology 68.4 4 Biallelic MCM10 Deficiency Presenting with Natural Killer Cell Deficiency, Poikiloderma and EBV-Associated Malignancy. Journal of clinical immunology 56.0 5 A qualitative exploration of the psychosocial burden and coping among adolescents and young adults with hematologic malignancies. BMC cancer 64.1 6 Preliminary Psychometric Evaluation of an Ultraviolet Radiation-Related Questionnaire in a Case-Control Sample. Ocular oncology and pathology 70.4 7 Forty Years Later-Complications and Mortality Associated with Cultured Epithelial Autografts in Burn Patients: A Systematic Review. Bioengineering (Basel, Switzerland) 78.1 8 Early Cardiotoxicity in Pediatric Patients with Acute Lymphoblastic Leukemia and Hodgkin Lymphoma: Incidence, Risk Factors, and Clinical Implications. Children (Basel, Switzerland) 74.62 9 Evaluating the Role of Anti-PEG Antibodies in Hypersensitivity to PEG-Asparaginase Through Clinically Relevant Cut-Points Defined by ELISA and Surface Plasmon Resonance. Pharmaceutics 62.0 10 Pediatric Microbiota: Evidence and Future Perspectives-A Conference Report. Microorganisms 65.0 11 A Bias-Aware Analytic Framework for Real-World Data with AI-Audited Workflows: Application to Opioid Ordering in Pediatric Oncology. Bioengineering (Basel, Switzerland) 73.2 12 All-Trans Retinoic Acid Nanocrystals for Enhanced Anticancer Activity Against Neuroblastoma Cancer Stem Cells. Pharmaceutics 53.3 13 Contribution of MTHFR C677T and A1298C Variants to Retinoblastoma Risk in Mexican Children. Genes 64.5 14 EBUS-Guided Cryobiopsy in a Pediatric Inflammatory Mediastinal Tumor With ROS1 Fusion: A Case Report. Pediatric pulmonology 39.0 15 Epidemiology of Kaposi's Sarcoma in Uzbekistan, 2016-2024: Gender-, Age-, and Region-Specific Differences. Asian Pacific journal of cancer prevention : APJCP 37.0 16 Design and Validation of Evidence-Based Peripheral Chemotherapy-Induced Neuropathy Guideline Among the Children with Cancer. Asian Pacific journal of cancer prevention : APJCP 75.34 17 Institutional and Demographic Barriers to Cervical Cancer Screening among Women in Rivers State, Nigeria. Asian Pacific journal of cancer prevention : APJCP 59.5 18 Endoscopic endonasal management of giant pediatric craniopharyngioma. Neurosurgical focus: Video 54.0 19 Keyhole endoscopic resection of pediatric craniopharyngioma via a precoronal transventricular transforaminal approach: "small door, big win.": Two-dimensional operative video. Neurosurgical focus: Video 54.0 20 Subpial dissection technique in endoscopic endonasal surgery for craniopharyngiomas with supradiaphragmatic extension. Neurosurgical focus: Video 35.0 21 Modern craniopharyngioma management: three illustrative cases with distinct therapeutic strategies. Neurosurgical focus: Video 62.04 22 Management of a giant pediatric craniopharyngioma: staged endoscopic endonasal and cranial approaches. Neurosurgical focus: Video 54.0 23 Excision of pediatric craniopharyngioma with complicated features: the value of additional "tailored" cavernous sinus exposure in the standard pterional approach. Neurosurgical focus: Video 56.4 24 Incidental Mandibular Intraosseous Findings in Neurofibromatosis Type 1: CBCT and MRI Features Influencing Clinical Management. Nigerian journal of clinical practice 60.8 25 Mitochondria as Key Players in Sarcoma Development, Progression and Drug Resistance: From Mechanistic Insights to New Treatment Opportunities. Biomolecules 70.6 26 Anodal Transcranial Direct Current Stimulation Reduces Neuroinflammation and Cholinergic Dysregulation After Young Adult Traumatic Brain Injury. Biomolecules 41.7 27 The Antigen-Presentation Bottleneck in Pediatric Solid Tumors: Developmental Antigens, MHC-I Suppression, and Therapeutic Restoration of Tumor Immune Recognition. Biomolecules 66.44 28 Factors Associated with Ventriculoperitoneal Shunt Placement Following Posterior Fossa Tumor Resection in Children: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania) 75.0 29 Clinical outcomes and prognostic factors in pediatric acute myeloid leukemia with monocytic differentiation: a single-center cohort study from Egypt. Frontiers in oncology 77.8 30 Multi-cohort screening of PANoptosis-related genes reveals PARP1 as a key target, and AZD5305 exerts anti-tumor effects in neuroblastoma. Frontiers in oncology 62.2 31 Extensive vertebral compression fractures as the initial manifestation of childhood B-cell acute lymphoblastic leukemia despite limited peripheral blood abnormalities: a case report. Frontiers in pediatrics 51.4 32 Cervical cancer screening willingness and associated health beliefs among predominantly college-educated young women attending gynecology clinics in Shenzhen, China. Frontiers in public health 59.0
PATIENT-FRIENDLY SUMMARY

Outcome of 421 adult patients with Philadelphia-negative acute lymphoblastic leukemia treated under an intensive program inspired by the GIMEMA LAL1913 clinical trial: a Campus ALL study.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic